Welcome to our dedicated page for Ge Healthcare Technologies SEC filings (Ticker: GEHC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The GE HealthCare Technologies Inc. (GEHC) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a Delaware corporation with common stock listed on Nasdaq under the symbol GEHC, GE HealthCare submits periodic and current reports that offer detail on its financial condition, governance, and significant corporate events.
Among the key documents investors often review are Form 10-K annual reports and Form 10-Q quarterly reports, which contain information on the company’s operations across its Imaging, Advanced Visualization Solutions, Patient Care Solutions, and Pharmaceutical Diagnostics businesses. In addition, Form 8-K current reports disclose material events. Recent 8-K filings have described items such as a three-year senior unsecured term loan credit facility, the issuance of senior notes due 2028 and 2035, the intended use of proceeds in connection with an announced acquisition of Intelerad Medical Systems, quarterly financial results, and changes to the board of directors.
Investors interested in GEHC can also use this page to track other filing types, such as registration statements and, when applicable, proxy materials related to governance matters. These documents help explain the company’s capital structure, including senior notes and credit facilities, and outline covenants, events of default, and other terms referenced in the filings.
Stock Titan enhances access to GE HealthCare’s filings by pairing real-time updates from the SEC’s EDGAR system with AI-powered summaries that highlight key points in lengthy documents. This can help users quickly understand the implications of new 10-K, 10-Q, and 8-K filings, as well as monitor developments related to financing arrangements, acquisitions, and other significant events disclosed by GE HealthCare Technologies Inc.
GE HealthCare Technologies Inc. Chief Financial Officer James Saccaro purchased 3,310 shares of Common Stock in an open-market transaction on May 1, 2026 at a weighted average price of $60.5997 per share. Following this purchase, he directly owns 87,471 shares. The filing notes the shares were bought in multiple trades at prices ranging from $60.59 to $60.60 per share.
GE HealthCare Technologies Inc. General Counsel and Corporate Secretary Frank R. Jimenez reported an open-market purchase of 1,750 shares of common stock at a price of $60.45 per share. Following this transaction, he directly owns 93,932 shares of GE HealthCare common stock.
GE HealthCare Technologies Inc. President and CEO Peter J. Arduini made an open-market purchase of company stock. On this date, he bought 4,169 shares of common stock at $59.925 per share.
After this transaction, Arduini directly owns 259,424 shares of GE HealthCare common stock. This filing shows a net increase in his personal shareholding through a straightforward open-market purchase.
GE HealthCare Technologies Inc reported that Vanguard Capital Management beneficially owned 33,370,111 shares of common stock, representing 7.31% of the class as of 03/31/2026. The filing shows sole voting power for 4,505,923 shares and sole dispositive power for 33,370,111 shares, and includes a disclosure that ownership reflects holdings of Vanguard affiliates and managed funds.
GE HealthCare Technologies Inc reported that Vanguard Capital Management beneficially owned 33,370,111 shares of common stock, representing 7.31% of the class as of 03/31/2026. The filing shows sole voting power for 4,505,923 shares and sole dispositive power for 33,370,111 shares, and includes a disclosure that ownership reflects holdings of Vanguard affiliates and managed funds.
GE HealthCare Technologies reported first‑quarter 2026 revenue of $5.13 billion, up from $4.78 billion a year earlier, driven by higher product and service sales across segments. Net income attributable to GE HealthCare fell to $389 million from $564 million as operating income declined to $515 million from $629 million, pressured in part by restructuring, acquisition‑related costs, and higher tariffs.
The company closed the $2.30 billion cash acquisition of Intelerad, adding significant imaging software capabilities and increasing goodwill and definite‑lived intangibles. Operating cash flow was $290 million, while investing activities used $2.50 billion, largely for Intelerad. GE HealthCare also repurchased $100 million of stock and ended the quarter with $2.29 billion in cash and $10.13 billion of borrowings.
GE HealthCare Technologies reported first‑quarter 2026 revenue of $5.13 billion, up from $4.78 billion a year earlier, driven by higher product and service sales across segments. Net income attributable to GE HealthCare fell to $389 million from $564 million as operating income declined to $515 million from $629 million, pressured in part by restructuring, acquisition‑related costs, and higher tariffs.
The company closed the $2.30 billion cash acquisition of Intelerad, adding significant imaging software capabilities and increasing goodwill and definite‑lived intangibles. Operating cash flow was $290 million, while investing activities used $2.50 billion, largely for Intelerad. GE HealthCare also repurchased $100 million of stock and ended the quarter with $2.29 billion in cash and $10.13 billion of borrowings.
GE HealthCare Technologies Inc. reported mixed first quarter 2026 results, combining solid revenue growth with weaker profitability and a reduced full‑year profit outlook.
Total revenues were $5.1 billion, up 7.4%, with Organic revenue growth of 2.9%, driven primarily by Pharmaceutical Diagnostics, Advanced Visualization Solutions, and Imaging across the U.S., EMEA, and Rest of World. Net income attributable to GE HealthCare fell to $389 million from $564 million, as net income margin declined to 7.6% from 11.8%. Adjusted EBIT was $691 million versus $715 million, with Adjusted EBIT margin at 13.5% compared with 15.0%. Diluted EPS was $0.85 versus $1.23, while Adjusted EPS was $0.99 versus $1.01.
Segment results were varied: Pharmaceutical Diagnostics revenue rose to $770 million with 9.7% Organic growth, but Patient Care Solutions revenue declined to $704 million with an 8.1% Organic decline and sharply lower EBIT. Management cited a discrete PDx supplier issue, higher memory chips, oil, and freight costs, and tariffs as margin headwinds, noting the PDx issue has been resolved.
Cash from operating activities was $290 million and Free cash flow was $112 million, both up year‑over‑year. The company closed the $2.3 billion Intelerad acquisition, ended the quarter with $2.3 billion of cash and cash equivalents, $10.1 billion of total debt, repurchased 1.4 million shares for $100 million, and declared a $0.035 per‑share dividend.
For full‑year 2026, GE HealthCare reaffirmed Organic revenue growth guidance of 3.0% to 4.0% but reduced profitability expectations. Adjusted EBIT margin guidance is now 15.4% to 15.7%, down from 15.8% to 16.1%. Adjusted EPS is guided to $4.80 to $5.00, versus prior guidance of $4.95 to $5.15, and Free cash flow is now expected to be approximately $1.6 billion versus prior guidance of approximately $1.7 billion. Management expects mid‑ to high‑single digit Adjusted EPS growth, assuming more pronounced inflation but partly offset by pricing and cost actions.
GE HealthCare Technologies Inc. reported mixed first quarter 2026 results, combining solid revenue growth with weaker profitability and a reduced full‑year profit outlook.
Total revenues were $5.1 billion, up 7.4%, with Organic revenue growth of 2.9%, driven primarily by Pharmaceutical Diagnostics, Advanced Visualization Solutions, and Imaging across the U.S., EMEA, and Rest of World. Net income attributable to GE HealthCare fell to $389 million from $564 million, as net income margin declined to 7.6% from 11.8%. Adjusted EBIT was $691 million versus $715 million, with Adjusted EBIT margin at 13.5% compared with 15.0%. Diluted EPS was $0.85 versus $1.23, while Adjusted EPS was $0.99 versus $1.01.
Segment results were varied: Pharmaceutical Diagnostics revenue rose to $770 million with 9.7% Organic growth, but Patient Care Solutions revenue declined to $704 million with an 8.1% Organic decline and sharply lower EBIT. Management cited a discrete PDx supplier issue, higher memory chips, oil, and freight costs, and tariffs as margin headwinds, noting the PDx issue has been resolved.
Cash from operating activities was $290 million and Free cash flow was $112 million, both up year‑over‑year. The company closed the $2.3 billion Intelerad acquisition, ended the quarter with $2.3 billion of cash and cash equivalents, $10.1 billion of total debt, repurchased 1.4 million shares for $100 million, and declared a $0.035 per‑share dividend.
For full‑year 2026, GE HealthCare reaffirmed Organic revenue growth guidance of 3.0% to 4.0% but reduced profitability expectations. Adjusted EBIT margin guidance is now 15.4% to 15.7%, down from 15.8% to 16.1%. Adjusted EPS is guided to $4.80 to $5.00, versus prior guidance of $4.95 to $5.15, and Free cash flow is now expected to be approximately $1.6 billion versus prior guidance of approximately $1.7 billion. Management expects mid‑ to high‑single digit Adjusted EPS growth, assuming more pronounced inflation but partly offset by pricing and cost actions.
GE HealthCare Technologies Inc Schedule 13G/A amendment shows The Vanguard Group reporting 0 shares and 0% beneficial ownership of Common Stock as of the amendment. The filing notes an internal realignment on 01/12/2026 that led to disaggregated reporting by Vanguard subsidiaries.
GE HealthCare Technologies Inc. is asking stockholders to vote at its virtual 2026 annual meeting on May 7, 2026. Holders of 456,290,143 common shares as of March 9, 2026 can vote on three items: electing eight directors for one-year terms, an advisory say‑on‑pay vote on 2025 executive compensation, and ratifying Deloitte & Touche LLP as independent auditor for 2026.
The company highlights 2025 revenue of $20.6 billion, record backlog, and earnings per share growth driven by volume and productivity despite tariff impacts. The board emphasizes strong governance, with seven of eight nominees independent, majority voting, proxy access, no poison pill or dual‑class shares, and a 15‑year director term limit. Executive pay is positioned as performance‑based and long‑term, with rigorous stock ownership requirements, a broad clawback policy, and prohibitions on hedging and pledging.
Lobo Kevin reported acquisition or exercise transactions in this Form 4 filing.
GE HealthCare Technologies Inc. director Kevin Lobo received an equity award of 777 restricted stock units of common stock. These RSUs were granted at no cash cost to him and represent compensation rather than an open-market purchase or sale.
According to the award terms, 100% of the 777 restricted stock units will vest on the earlier of GE HealthCare’s next annual meeting of stockholders or March 13, 2027. Each vested unit entitles him to receive one share of GE HealthCare common stock, and settlement may be deferred under the company’s non-employee director compensation plan.